<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anticoagulant rodenticide poisoning: Clinical manifestations and diagnostic evaluation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anticoagulant rodenticide poisoning: Clinical manifestations and diagnostic evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anticoagulant rodenticide poisoning: Clinical manifestations and diagnostic evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane P Calello, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erica L Liebelt, MD, FACMT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H454905268"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic reviews the clinical manifestations and diagnosis of anticoagulant rodenticide (also called long-acting anticoagulant rodenticide; LAAR) poisoning.</p><p>The management of anticoagulant rodenticide poisoning and an overview of rodenticide poisonings other than anticoagulant rodenticides is provided separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106877.html" rel="external">"Anticoagulant rodenticide poisoning: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/94398.html" rel="external">"Overview of rodenticide poisoning"</a>.)</p><p></p><p class="headingAnchor" id="H454905274"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Anticoagulant compounds are the most commonly used rodenticides in most of the world. The process of controlling rodent populations is imperative to human health but poses challenges when the rodenticide compounds used are also toxic to humans and domestic animals. The ideal rodenticide is highly toxic to rodents in small amounts but relatively nontoxic in small quantities to non-target species. The anticoagulant rodenticides best fit this criteria [<a href="#rid1">1</a>]. Anticoagulant rodenticides came into use in the 1940s with the use of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. The emergence of warfarin-resistant rats prompted the development of superwarfarins, or long-acting anticoagulants such as brodifacoum, bromadiolone, and chlorophacinone. Because of their availability, anticoagulant rodenticides are also the most common cause of rodenticide poisoning exposures reported annually in resource-rich countries such as the United States and the United Kingdom [<a href="#rid2">2,3</a>].</p><p>In the United States, brodifacoum remains common although use may be declining due to increased use of bromethalin [<a href="#rid3">3</a>]; however, global differences exist. In the United Kingdom, difenacoum, brodifacoum, and bromadiolone are most common [<a href="#rid4">4</a>]. In the developing world, the use of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> rodenticides has led to tragic inadvertent exposures in newborns as well as the ingestion of contaminated foodstuff with resultant fatalities [<a href="#rid5">5,6</a>]. </p><p>In the United States during 2018, there was an outbreak of anticoagulant rodenticide poisoning; there were reports of over 150 patients with serious bleeding and at least seven deaths from use of synthetic cannabinoids contaminated with brodifacoum [<a href="#rid7">7-11</a>]. In Israel during 2021 to 2022, there was a similar outbreak involving 98 patients and four deaths [<a href="#rid12">12</a>].</p><p>Throughout the world, the overwhelming majority of anticoagulant rodenticide exposures occur in young children, who generally ingest small volumes and have no significant coagulopathy [<a href="#rid3">3,6,13,14</a>]. However, patients with intentional or occupational exposures develop coagulopathy much more frequently.</p><p class="headingAnchor" id="H511414414"><span class="h1">PHARMACOLOGY</span></p><p class="headingAnchor" id="H454905286"><span class="h2">Formulations and chemical agents</span><span class="headingEndMark"> — </span>Anticoagulant rodenticides are widely used in domestic, industrial and agricultural settings. It is essential to identify the specific anticoagulant rodenticide involved with any exposure to accurately determine potential toxicity.</p><p>Product formulations include [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cereal bait</p><p class="bulletIndent1"><span class="glyph">●</span>Pellets</p><p class="bulletIndent1"><span class="glyph">●</span>Loose grain</p><p class="bulletIndent1"><span class="glyph">●</span>Blocks</p><p class="bulletIndent1"><span class="glyph">●</span>Paste</p><p class="bulletIndent1"><span class="glyph">●</span>Tracking powder</p><p class="bulletIndent1"><span class="glyph">●</span>Wax block</p><p></p><p>Baits may be treated with brightly colored dye and bittering agents (such as denatonium benzoate) to decrease the appeal to non-target species. <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> baits are generally 0.025 to 0.05 percent active ingredient. Most long-acting rodenticide baits are sold at a lower concentration to the public, typically 0.0025 percent [<a href="#rid6">6</a>]. However, high concentration formulations that have &gt;90 percent anticoagulant ingredients are commercially available [<a href="#rid15">15</a>].</p><p>First-generation anticoagulants such as <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and coumatetralyl have been in use as rodenticides since the 1940s. However, the appearance of warfarin-resistant rat populations prompted the development and use of second-generation agents, which due to the presence of a polycyclic side chain and higher lipid solubility are more potent with a longer duration of action [<a href="#rid16">16,17</a>]. While many days of feeding on warfarin may be needed to kill a rodent, a single day's exposure to a second-generation agent is usually lethal [<a href="#rid18">18</a>].</p><p>Also called "superwarfarins" or "long-acting" agents, the second generation anticoagulant rodenticides include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The 4-hydroxycoumarin derivatives: brodifacoum (D-Con), bromadiolone, difenacoum, and flocoumafen</p><p class="bulletIndent1"><span class="glyph">●</span>The indanedione derivatives: chlorophacinone and diphacinone</p><p></p><p class="headingAnchor" id="H466431236"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>Both first- and second-generation anticoagulants work by inhibiting vitamin K-1,25 epoxide reductase, which is required for the regeneration of vitamin K and subsequent activation (gamma-carboxylation) of vitamin K-dependent clotting factors II, VII, IX, and X, and proteins C, S, and Z (<a class="graphic graphic_figure graphicRef61632" href="/d/graphic/61632.html" rel="external">figure 1</a>). As such, immediate effects are not seen even after massive exposure to these agents, as time is required for the existing coagulation factor supply to decrease and fail to replenish. Laboratory evidence of coagulopathy is typically delayed for 24 to 48 hours after exposure. (See  <a class="medical medical_review" href="/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a> and <a class="local">'Toxicokinetics'</a> below.)</p><p class="headingAnchor" id="H454905298"><span class="h2">Toxicokinetics</span><span class="headingEndMark"> — </span>The toxicokinetics of anticoagulant rodenticides are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absorption</strong> – Both <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and long-acting anticoagulants are well-absorbed orally and extensively protein-bound. Most undergo hepatic p450 metabolism [<a href="#rid6">6,16,19-21</a>]. Inhalational absorption can occur with occupational exposure. Dermal absorption has also been described in a fatal newborn epidemic of warfarin-contaminated talcum powder and in adults with prolonged dermal exposure [<a href="#rid5">5,22</a>]. However, poisoning with coagulopathy most commonly occurs after ingestion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Onset of action</strong> – The onset of coagulopathy requires coagulation factor activity to drop below 30 percent of normal. The depletion of factor VII, the vitamin K-dependent factor with the shortest plasma half-life (three to five hours), produces the first signs of coagulopathy. Laboratory evidence of coagulopathy (elevated prothrombin time [PT] and international normalized ratio [INR], decreased prothrombin concentrations) is usually evident within 48 hours after exposure; however, long-acting rodenticide poisoning may exhibit significant latency of several days [<a href="#rid6">6</a>]. Second-generation agents have a much longer duration of effect, which is attributable to a number of factors including hepatic accumulation, high lipid solubility, and prolonged elimination [<a href="#rid6">6,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of effect and elimination</strong> – The duration of effect depends upon the elimination rate of a given compound. Although kinetics distort unpredictably in overdose, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> has a much shorter elimination half-life than long-acting anticoagulants, and there is significant variability between long-acting agents. In overdose, warfarin follows a first-order elimination curve with a half-life of 21.7 hours [<a href="#rid23">23</a>]. Second-generation anticoagulants demonstrate zero-order, saturation-dependent kinetics in overdose. Half-lives of brodifacoum in overdose demonstrate a biphasic pattern, with initial values of 0.75 days followed by a half-life ranging from 16 to 62 days [<a href="#rid24">24-26</a>].</p><p></p><p class="headingAnchor" id="H454905304"><span class="h2">Toxic dose</span><span class="headingEndMark"> — </span>We encourage consultation with a regional poison control center to help determine the potential toxicity of any anticoagulant rodenticide exposure. (See <a class="local">'Regional poison control centers'</a> below.)</p><p>There is <strong>no</strong> predictable relationship between dose ingested and serum concentrations for anticoagulant rodenticides. A single overdose of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> up to 1 mg/kg, or 0.7 mg/kg in a child, which corresponds to the typical pediatric ingestion of less than one packet of a low concentration anticoagulant rodenticide, can be expected to have little effect. The prothrombin time may elevate within 24 hours and normalize within five days [<a href="#rid16">16</a>]. There is less predictability surrounding long-acting anticoagulant dose-response relationships.</p><p class="headingAnchor" id="H454905322"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H466432434"><span class="h2">History</span><span class="headingEndMark"> — </span>During the history, the clinician should determine the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Specific agent ingested</p><p class="bulletIndent1"><span class="glyph">●</span>Amount ingested</p><p class="bulletIndent1"><span class="glyph">●</span>Time of ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>Any coingestions</p><p></p><p>The clinician should also make every effort to identify the specific rodenticide and the circumstances of the exposure to guide care. In regions where a "signal word" appears on the product label, anticoagulant rodenticides are identified by the word "<strong>Caution</strong>." A regional poison control center can also assist with product identification. (See  <a class="medical medical_review" href="/d/html/94398.html" rel="external">"Overview of rodenticide poisoning", section on 'Definition and classification'</a> and <a class="local">'Regional poison control centers'</a> below.)</p><p>The clinician should also maintain vigilance for intentional ingestion or administration of anticoagulant rodenticides when evaluating patients with spontaneous bleeding of unclear etiology. These agents have been well described as a means of producing bleeding in cases of malicious poisoning, factitious disorder (Munchausen syndrome), and medical child abuse (Munchausen syndrome by proxy). Specific concentrations of anticoagulant rodenticides can be obtained when these diagnoses are suspected to confirm exposure. (See  <a class="medical medical_review" href="/d/html/7765.html" rel="external">"Factitious disorder imposed on self (Munchausen syndrome)"</a> and  <a class="medical medical_review" href="/d/html/6608.html" rel="external">"Medical child abuse (Munchausen syndrome by proxy)"</a>.)</p><p>The past medical history should also determine whether the patient has an increased risk of bleeding because of concurrent liver disease, anticoagulant therapy, or a coagulation disorder.</p><p class="headingAnchor" id="H466432512"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Patients with anticoagulant rodenticide exposure should have assessment of vital signs and a complete physical examination. Patients examined within 24 hours of exposure will not have yet developed coagulopathy and should not be expected to have signs of bruising or bleeding. (See <a class="local">'Toxicokinetics'</a> above.)</p><p>Large ingestions, often suicidal in nature and involving consumption of bait pellets by adolescents and adults, can lead to profound and prolonged anticoagulation with serious or life-threatening hemorrhage, including gastrointestinal, genitourinary, and intracranial bleeding commencing at 24 to 48 hours after exposure [<a href="#rid18">18,24,26,27</a>]. The most common area of significant bleeding seen after exposure is frank hematuria with abdominal or flank pain [<a href="#rid6">6,18,24,25,28</a>]. After ingestion of second-generation agents (superwarfarins), coagulopathy may be present for many months and recurrent bleeding is possible [<a href="#rid18">18,29</a>]. (See <a class="local">'Toxicokinetics'</a> above.)</p><p>Bleeding is assessed according to the site, rate of hemorrhage, and amount of blood loss. We define serious/major bleeding as bleeding that is potentially associated with significant blood loss requiring blood transfusion or bleeding into a critical closed space (eg, intracranial bleeding, compartment syndrome). Major bleeding may also include bleeding requiring an intervention for management (eg, surgery, interventional radiology procedures, endoscopic treatments). Major bleeding has a significant risk of immediate morbidity, regardless of the cause. Various definitions of major bleeding are presented in the table (<a class="graphic graphic_table graphicRef71353" href="/d/graphic/71353.html" rel="external">table 1</a>).</p><p>Patients with major bleeding may demonstrate signs of hemorrhagic shock (eg, pallor, tachycardia, tachypnea, narrowed pulse pressure, and hypotension) and for patients with intracranial bleeding, signs of increased intracranial pressure (eg, bradycardia, hypertension, irregular respirations, coma, and focal neurologic deficits). (See  <a class="medical medical_review" href="/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock", section on 'Features of shock'</a> and  <a class="medical medical_review" href="/d/html/1659.html" rel="external">"Evaluation and management of elevated intracranial pressure in adults", section on 'Clinical manifestations'</a>.)</p><p>Minor, but still clinically significant, bleeding includes bleeding requiring a health care assessment or less invasive treatment, such as epistaxis, gum or oral bleeding, easy bruising/ecchymosis, or heavy menstrual bleeding. </p><p>Patients with repeated chronic ingestions may also have signs of bruising and minor or major bleeding.</p><p class="headingAnchor" id="H454905328"><span class="h1">ANCILLARY STUDIES</span></p><p class="headingAnchor" id="H466432121"><span class="h2">Acute or chronic exposure</span><span class="headingEndMark"> — </span>The laboratory evaluation of patients with anticoagulant rodenticide exposure varies according to the estimated ingested dose and the type of exposure. We encourage consultation with a regional poison control center to assist in determining whether the ingested dose is toxic or nontoxic. (See <a class="local">'Regional poison control centers'</a> below.)</p><p>The suggested approach is as follows:</p><p class="headingAnchor" id="H2297251919"><span class="h3">Unintentional nontoxic exposures</span><span class="headingEndMark"> — </span>No laboratory assessment is needed in children or older patients with clearly unintentional ingestion of nontoxic amounts of anticoagulant rodenticides and who are <strong>not</strong> on anticoagulant therapy. In the past, some experts suggested that all of these patients undergo testing of prothrombin time (PT) and international normalized ratio (INR) at 48 hours based upon small case series that document occasional instances of coagulopathy [<a href="#rid30">30</a>]. However, serious bleeding has not been reported with ingestion of less than one packet of anticoagulant rodenticide despite regional poison center documentation of thousands of such exposures over the past 40 years [<a href="#rid6">6,31,32</a>].</p><p>Asymptomatic patients on anticoagulant therapy who have an unintentional small exposure to anticoagulant rodenticides warrant a baseline measurement of PT and INR with a repeated measurement 48 to 72 hours after exposure.</p><p class="headingAnchor" id="H2706594283"><span class="h3">Unintentional toxic exposures</span><span class="headingEndMark"> — </span>Patients with unintentional toxic exposures and who are otherwise healthy and not receiving anticoagulant therapy warrant measurement of PT and INR at 48 to 72 hours after exposure. (See <a class="local">'Toxic dose'</a> above.)</p><p>Patients on anticoagulant therapy or with underlying medical conditions (eg, liver disease) that may be associated with abnormal coagulation should have a baseline measurement of PT and INR as soon as possible after the ingestion and repeated measurement 48 to 72 hours after exposure.</p><p class="headingAnchor" id="H3160718334"><span class="h3">Intentional or chronic exposures</span><span class="headingEndMark"> — </span>We recommend that patients with intentional (self-harm, abuse, or malicious intent) or chronic ingestions, regardless of reported amount, undergo measurement of a PT, an INR, and a partial thromboplastin time (aPTT) during the initial presentation to the emergency department. Soon after ingestion of an anticoagulant rodenticide, these studies will be normal, but measurement will provide a baseline value.</p><p>For acute exposures, the PT and INR should then be repeated at 36 to 48 hours. With ingestions likely to cause anticoagulation and/or bleeding, the PT and INR will typically become abnormal at 12 to 24 hours and peak at 36 to 72 hours after ingestion [<a href="#rid24">24</a>]. If no coagulopathy or bleeding is present at 36 to 48 hours after exposure, no further measurement is indicated.</p><p>Patients who are suicidal should also undergo laboratory assessment for coingestants based upon clinical findings and warrant measurement of an <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> concentration even if asymptomatic.</p><p class="headingAnchor" id="H1928225391"><span class="h3">Patients with coagulopathy or bleeding</span><span class="headingEndMark"> — </span>Coagulopathy from rodenticide poisoning is characterized by prolongation of the PT, INR, and aPTT.</p><p></p><p>Additional studies should be obtained in patients with any evidence of bleeding on physical examination or coagulopathy on laboratory testing and include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential</p><p class="bulletIndent1"><span class="glyph">●</span>Type and screen for blood products or, if significant bleeding, type and cross match</p><p class="bulletIndent1"><span class="glyph">●</span>Urine dipstick for blood</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma fibrinogen and serum fibrin degradation products</p><p class="bulletIndent1"><span class="glyph">●</span>Stool for guaiac</p><p></p><p>Other laboratory or imaging studies may also be indicated depending upon the specific sites of bleeding (eg, electrolytes, blood urea nitrogen, serum creatinine, and ultrasound or computed tomography [CT] of the abdomen for major genitor-urinary bleeding; CT of the head for intracranial bleeding).</p><p>The definitive test for anticoagulant rodenticide poisoning is quantitative concentration measurement by liquid chromatography-tandem mass spectrometry in serum [<a href="#rid33">33</a>]. However, these tests are difficult to obtain in a timely fashion to guide clinical management of acute overdoses, and are primarily used to confirm exposure (eg, patients with factitious disorder or deliberate administration of a rodenticide as part of medical child abuse or other criminal activity). A brodifacoum or bromadiolone concentration &lt;10 ng/mL has been associated with normal coagulation parameters and is likely safe, although an evidence-based safe threshold does not exist [<a href="#rid18">18,34</a>].</p><p>Some parameters that may be of use to assess toxicity beyond standard coagulation testing include clotting factor activity, prothrombin activity and Vitamin K 2,3 epoxide concentration with epoxide:Vitamin K1 ratio. These may elucidate the diagnosis if there is not a clear history of rodenticide exposure. The utility of vitamin K 2,3 epoxide and the epoxide:Vitamin K1 ratio is mostly limited to the setting of occupational monitoring.</p><p class="headingAnchor" id="H454905334"><span class="h2">Occupational monitoring</span><span class="headingEndMark"> — </span>Workplace exposure has been observed in patients involved in the manufacture and application of anticoagulant rodenticides, in particular when appropriate industrial hygiene is not performed [<a href="#rid22">22,35</a>]. Industrial exposure may result in persistent abnormalities in vitamin K metabolism for many months after cessation of exposure and resolution of coagulopathy [<a href="#rid6">6,17,35,36</a>]. A vitamin K 2,3-epoxide concentration may be a better long-term marker of exposure than standard coagulation parameters. After a vitamin K challenge, a normal epoxide concentration should be &lt;30 ng/mL [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H466432194"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of anticoagulant rodenticide <strong>exposure</strong> is made based upon history.</p><p>The diagnosis of anticoagulant rodenticide <strong>poisoning</strong> is made when coagulopathy is identified by clinical bruising and bleeding and/or prolonged prothrombin time (PT) and international normalized ratios (INRs) obtained 36 to 48 hours after ingestion. In patients without a history of exposure but unexplained bruising or bleeding, the presence of measurable rodenticide concentrations in the serum also establishes the diagnosis.</p><p class="headingAnchor" id="H479032"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>In patients who develop coagulopathy or bleeding, the diagnosis of anticoagulant rodenticide is usually obtained from the history.</p><p>However, some patients present with unexplained bleeding. The diagnostic approach to these patients includes consideration of other causes of bleeding and is discussed separately. (See  <a class="medical medical_review" href="/d/html/5936.html" rel="external">"Approach to the child with bleeding symptoms", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H2535142676"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of anticoagulant rodenticide poisoning is discussed separately. (See  <a class="medical medical_review" href="/d/html/106877.html" rel="external">"Anticoagulant rodenticide poisoning: Management"</a>.)</p><p class="headingAnchor" id="H535393009"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2144304355"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p>In addition, some hospitals have clinical and/or medical toxicologists available for bedside consultation and/or inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of toxic exposures.</p><p class="headingAnchor" id="H543019437"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H454905353"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Anticoagulants rodenticides (warfarins and "superwarfarins") work by inhibiting vitamin K-1,25 epoxide reductase, which is required for the regeneration of vitamin K and subsequent activation (gamma-carboxylation) of vitamin K-dependent clotting factors II, VII, IX, and X, and proteins C, S, and Z. (See <a class="local">'Formulations and chemical agents'</a> above and <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Large ingestions, often suicidal in nature and involving consumption of bait pellets by adolescents and adults, can lead to profound and prolonged anticoagulation with serious or life-threatening hemorrhage, including gastrointestinal, genitourinary, and intracranial bleeding commencing at 24 to 48 hours after exposure. The most common area of significant bleeding seen after exposure is frank hematuria with abdominal or flank pain. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">Patients examined within 24 hours of exposure will <strong>not</strong> have yet developed coagulopathy and should <strong>not</strong> be expected to have signs of bruising or bleeding. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of ancillary studies</strong> – Laboratory evidence of coagulopathy is typically delayed for 24 to 48 hours after exposure. The laboratory evaluation of patients with anticoagulant rodenticide exposure varies according to the estimated ingested dose and the type of exposure (see <a class="local">'Ancillary studies'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unintentional nontoxic exposures</strong> – No laboratory assessment is needed in children or older patients with clearly unintentional ingestion of nontoxic amounts of anticoagulant rodenticides who are not on anticoagulant therapy or who do not have an underlying medical condition (eg, liver disease) that is associated with abnormal coagulation. (See <a class="local">'Unintentional nontoxic exposures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unintentional toxic exposures</strong> – Patients with unintentional toxic exposures and who are otherwise healthy and not receiving anticoagulant therapy warrant measurement of prothrombin time (PT) and international normalized ratio (INR) at 48 to 72 hours after exposure. Patients on anticoagulant therapy or with underlying medical conditions (eg, liver disease) that may be associated with abnormal coagulation should have a baseline measurement of PT and INR as soon as possible after the ingestion and repeated measurement 48 to 72 hours after exposure. (See <a class="local">'Unintentional toxic exposures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intentional or chronic exposures – </strong>We recommend that patients with intentional (self-harm, abuse, or malicious intent) or chronic ingestions, regardless of reported amount, undergo measurement of a PT, an INR, and a partial thromboplastin time (aPTT) during the initial presentation to the emergency department. Patients who are suicidal should also undergo laboratory assessment for coingestants based upon clinical findings and warrant measurement of an <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> concentration even if asymptomatic. (See <a class="local">'Intentional or chronic exposures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with coagulopathy or bleeding</strong> – Additional studies should be obtained in patients with any evidence of bleeding on physical examination or coagulopathy on laboratory testing and include the following (see <a class="local">'Patients with coagulopathy or bleeding'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Complete blood count with differential</p><p class="bulletIndent3"><span class="glyph">-</span>Type and screen for blood products or, if significant bleeding, type and cross match</p><p class="bulletIndent3"><span class="glyph">-</span>Urine dipstick for blood</p><p class="bulletIndent3"><span class="glyph">-</span>Plasma fibrinogen and serum fibrin degradation products</p><p class="bulletIndent3"><span class="glyph">-</span>Stool for guaiac</p><p></p><p class="bulletIndent2">Other laboratory or imaging studies may also be indicated depending upon the specific sites of bleeding (eg, electrolytes, blood urea nitrogen, serum creatinine, and ultrasound or computed tomography [CT] of the abdomen for major genitor-urinary bleeding; CT of the head for intracranial bleeding).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of anticoagulant concentrations</strong> – Specific anticoagulant concentrations are difficult to obtain in a timely fashion to guide clinical management of acute overdoses, and are primarily used to confirm exposure (eg, patients with factitious disorder or deliberate administration of a rodenticide as part of medical child abuse or other criminal activity). (See <a class="local">'Acute or chronic exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of anticoagulant rodenticide <strong>exposure</strong> is made based upon history. The diagnosis of anticoagulant rodenticide <strong>poisoning</strong> is made when coagulopathy is identified by clinical bruising and bleeding and/or prolonged PT and INRs obtained 36 to 48 hours after ingestion. The presence of measurable rodenticide concentrations in the blood also establishes the diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– The management of anticoagulant rodenticide poisoning is discussed separately. (See  <a class="medical medical_review" href="/d/html/106877.html" rel="external">"Anticoagulant rodenticide poisoning: Management"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Hayes WJ. Pesticides Studied in Man, Williams &amp; Wilkins, Baltimore 1982.</li><li class="breakAll">Dawson A, Garthwaite D. Rodenticide usage by local authorities in Great Britain. In: Pesticide Usage Survey Report 185, F.a.R.A. Department for Environment (Ed). York UK 2001.</li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.</a></li><li class="breakAll">Dawson A, Garthwaite D. Rodenticide usage by local authorities in Great Britain. In: Pesticide Usage Survey Report 185, F.a.R.A. Department for Environment (Ed), York UK 2001.</li><li><a class="nounderline abstract_t">Martin-Bouyer G, Khanh NB, Linh PD, et al. Epidemic of haemorrhagic disease in Vietnamese infants caused by warfarin-contaminated talcs. Lancet 1983; 1:230.</a></li><li><a class="nounderline abstract_t">Watt BE, Proudfoot AT, Bradberry SM, Vale JA. Anticoagulant rodenticides. Toxicol Rev 2005; 24:259.</a></li><li><a class="nounderline abstract_t">Moritz E, Austin C, Wahl M, et al. Notes from the Field: Outbreak of Severe Illness Linked to the Vitamin K Antagonist Brodifacoum and Use of Synthetic Cannabinoids - Illinois, March-April 2018. MMWR Morb Mortal Wkly Rep 2018; 67:607.</a></li><li><a class="nounderline abstract_t">Devgun JM, Rasin A, Kim T, et al. An outbreak of severe coagulopathy from synthetic cannabinoids tainted with Long-Acting anticoagulant rodenticides. Clin Toxicol (Phila) 2020; 58:821.</a></li><li><a class="nounderline abstract_t">Bahouth MN, Kraus P, Dane K, et al. Synthetic cannabinoid-associated coagulopathy secondary to long-acting anticoagulant rodenticides: Observational case series and management recommendations. Medicine (Baltimore) 2019; 98:e17015.</a></li><li><a class="nounderline abstract_t">Kelkar AH, Smith NA, Martial A, et al. An Outbreak of Synthetic Cannabinoid-Associated Coagulopathy in Illinois. N Engl J Med 2018; 379:1216.</a></li><li><a class="nounderline abstract_t">Arepally GM, Ortel TL. Bad weed: synthetic cannabinoid-associated coagulopathy. Blood 2019; 133:902.</a></li><li><a class="nounderline abstract_t">Lurie Y, Nadir Y, Hoffman R, et al. An outbreak of severe coagulopathy in northern Israel among users of illicit synthetic cannabinoids adulterated with brodifacoum. Clin Toxicol (Phila) 2023; 61:429.</a></li><li><a class="nounderline abstract_t">Smolinske SC, Scherger DL, Kearns PS, et al. Superwarfarin poisoning in children: a prospective study. Pediatrics 1989; 84:490.</a></li><li><a class="nounderline abstract_t">Mullins ME, Brands CL, Daya MR. Unintentional pediatric superwarfarin exposures: do we really need a prothrombin time? Pediatrics 2000; 105:402.</a></li><li class="breakAll">Caravati EM, Erdman AR, Scharman EJ, et al. Long-acting anticoagulant rodenticide poisoning: An evidence-based consensus guideline for out-of-hospital management. Clinical Toxicol (Phila) 2007; 45:1.</li><li class="breakAll">Yip L. Anticoagulant rodenticides. In: Medical Toxicology, Dart RC, Caravati EM, McGuigan MA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.1497.</li><li><a class="nounderline abstract_t">Leck JB, Park BK. A comparative study of the effects of warfarin and brodifacoum on the relationship between vitamin K1 metabolism and clotting factor activity in warfarin-susceptible and warfarin-resistant rats. Biochem Pharmacol 1981; 30:123.</a></li><li><a class="nounderline abstract_t">Bruno GR, Howland MA, McMeeking A, Hoffman RS. Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing. Ann Emerg Med 2000; 36:262.</a></li><li class="breakAll">Lai M, Ewald M. Anticoagulants. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, Shannon MW, Borron SW, Burns MJ (Eds), Saunders, 2007. Vol 1051.</li><li><a class="nounderline abstract_t">Vandenbroucke V, Bousquet-Melou A, De Backer P, Croubels S. Pharmacokinetics of eight anticoagulant rodenticides in mice after single oral administration. J Vet Pharmacol Ther 2008; 31:437.</a></li><li><a class="nounderline abstract_t">Berny PJ, de Oliveira LA, Videmann B, Rossi S. Assessment of ruminal degradation, oral bioavailability, and toxic effects of anticoagulant rodenticides in sheep. Am J Vet Res 2006; 67:363.</a></li><li><a class="nounderline abstract_t">Spiller HA, Gallenstein GL, Murphy MJ. Dermal absorption of a liquid diphacinone rodenticide causing coagulaopathy. Vet Hum Toxicol 2003; 45:313.</a></li><li><a class="nounderline abstract_t">Hackett LP, Ilett KF, Chester A. Plasma warfarin concentrations after a massive overdose. Med J Aust 1985; 142:642.</a></li><li><a class="nounderline abstract_t">Hollinger BR, Pastoor TP. Case management and plasma half-life in a case of brodifacoum poisoning. Arch Intern Med 1993; 153:1925.</a></li><li><a class="nounderline abstract_t">Stanton T, Sowray P, McWaters D, Mount M. Prolonged anticoagulation with long-acting coumadin derivative: Case report of a brodifacoum poisoning with pharmacokinetic data. Blood 1988; 73:310a.</a></li><li><a class="nounderline abstract_t">Weitzel JN, Sadowski JA, Furie BC, et al. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood 1990; 76:2555.</a></li><li><a class="nounderline abstract_t">Stanton T, Sowray P, McWaters D, Mount M. Prolonged anticoagulation with long-acting coumadin derivative: Case report of a brodifacoum poisoning with pharmacokinetic data. Blood 1988; 72:310a.</a></li><li><a class="nounderline abstract_t">Guodong L, Jieyi W, Xiaobo P, et al. Retrospective analysis of clinical characteristics of and treatment strategies for patients with long-acting anticoagulant rodenticide poisoning. Basic Clin Pharmacol Toxicol 2022; 131:74.</a></li><li><a class="nounderline abstract_t">Watts RG, Castleberry RP, Sadowski JA. Accidental poisoning with a superwarfarin compound (brodifacoum) in a child. Pediatrics 1990; 86:883.</a></li><li class="breakAll">Su M. Anticoagulants. In: Goldfrank's Toxicologic Emergencies, 9th ed, Nelson LS, Lewin NA, Howland MA, et al (Eds), McGraw HIll Medical, New York 2011. p.861.</li><li><a class="nounderline abstract_t">Ingels M, Lai C, Tai W, et al. A prospective study of acute, unintentional, pediatric superwarfarin ingestions managed without decontamination. Ann Emerg Med 2002; 40:73.</a></li><li><a class="nounderline abstract_t">Shepherd G, Klein-Schwartz W, Anderson BD. Acute, unintentional pediatric brodifacoum ingestions. Pediatr Emerg Care 2002; 18:174.</a></li><li><a class="nounderline abstract_t">Chong YK, Mak TW. Superwarfarin (Long-Acting Anticoagulant Rodenticides) Poisoning: from Pathophysiology to Laboratory-Guided Clinical Management. Clin Biochem Rev 2019; 40:175.</a></li><li><a class="nounderline abstract_t">Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol 2007; 82:656.</a></li><li><a class="nounderline abstract_t">Svendsen SW, Kolstad HA, Steesby E. Bleeding problems associated with occupational exposure to anticoagulant rodenticides. Int Arch Occup Environ Health 2002; 75:515.</a></li><li><a class="nounderline abstract_t">Fristedt B, Sterner N. Warfarin intoxication from percutaneous absorption. Arch Environ Health 1965; 11:205.</a></li></ol></div><div id="topicVersionRevision">Topic 100310 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hayes WJ. Pesticides Studied in Man, Williams &amp; Wilkins, Baltimore 1982.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Dawson A, Garthwaite D. Rodenticide usage by local authorities in Great Britain. In: Pesticide Usage Survey Report 185, F.a.R.A. Department for Environment (Ed). York UK 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6130257" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemic of haemorrhagic disease in Vietnamese infants caused by warfarin-contaminated talcs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16499407" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anticoagulant rodenticides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29851941" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Notes from the Field: Outbreak of Severe Illness Linked to the Vitamin K Antagonist Brodifacoum and Use of Synthetic Cannabinoids - Illinois, March-April 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31797705" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : An outbreak of severe coagulopathy from synthetic cannabinoids tainted with Long-Acting anticoagulant rodenticides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31490385" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Synthetic cannabinoid-associated coagulopathy secondary to long-acting anticoagulant rodenticides: Observational case series and management recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30280655" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An Outbreak of Synthetic Cannabinoid-Associated Coagulopathy in Illinois.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30655273" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bad weed: synthetic cannabinoid-associated coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37293741" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An outbreak of severe coagulopathy in northern Israel among users of illicit synthetic cannabinoids adulterated with brodifacoum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2771552" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Superwarfarin poisoning in children: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10654963" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Unintentional pediatric superwarfarin exposures: do we really need a prothrombin time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10654963" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Unintentional pediatric superwarfarin exposures: do we really need a prothrombin time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10654963" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Unintentional pediatric superwarfarin exposures: do we really need a prothrombin time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7236301" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A comparative study of the effects of warfarin and brodifacoum on the relationship between vitamin K1 metabolism and clotting factor activity in warfarin-susceptible and warfarin-resistant rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10969235" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10969235" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19000263" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pharmacokinetics of eight anticoagulant rodenticides in mice after single oral administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16454646" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Assessment of ruminal degradation, oral bioavailability, and toxic effects of anticoagulant rodenticides in sheep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14640483" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dermal absorption of a liquid diphacinone rodenticide causing coagulaopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4000042" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Plasma warfarin concentrations after a massive overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8250654" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Case management and plasma half-life in a case of brodifacoum poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prolonged anticoagulation with long-acting coumadin derivative: Case report of a brodifacoum poisoning with pharmacokinetic data</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2265249" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prolonged anticoagulation with long-acting coumadin derivative: Case report of a brodifacoum poisoning with pharmacokinetic data</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35470573" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Retrospective analysis of clinical characteristics of and treatment strategies for patients with long-acting anticoagulant rodenticide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2251025" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Accidental poisoning with a superwarfarin compound (brodifacoum) in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2251025" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Accidental poisoning with a superwarfarin compound (brodifacoum) in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085076" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A prospective study of acute, unintentional, pediatric superwarfarin ingestions managed without decontamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12066002" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acute, unintentional pediatric brodifacoum ingestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31857739" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Superwarfarin (Long-Acting Anticoagulant Rodenticides) Poisoning: from Pathophysiology to Laboratory-Guided Clinical Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17022046" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Superwarfarin poisoning: a report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12172900" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bleeding problems associated with occupational exposure to anticoagulant rodenticides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5832250" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Warfarin intoxication from percutaneous absorption.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
